Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  BioCryst Pharmaceuticals, Inc.    BCRX

BIOCRYST PHARMACEUTICALS, INC. (BCRX)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

BioCryst Pharmaceuticals, Inc. : Commentary & Reports For: (NASDAQ: BCRX), (NYSE: GST)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/24/2013 | 07:45pm CEST

New York (April 24th, 2013) - BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) traded in the range of $1.75 and $1.97 during its latest trading session. The stock recorded the volume of 1.986 million shares. Currently, it is at $1.93, up 7.23 from its previous close. Its average daily trading volume stands at 1.085 million shares. Its MACD chart shows bullish trend and the stock is trading above its long term moving average price of $1.92. The company?s current market capitalization stands at $98.29 million.

BioCryst Pharmaceuticals stock is up 37.86 percent in the year 2013 so far while it lost 51.51 percent of its value in the past 52 weeks.

Find out if BCRX could maintain the momentum by getting the complete trend analysis report here:

http://www.monstertradingalerts.com/market-scan/?symbol=BCRX


Gastor Exploration Ltd. (NYSE: GST) stock is at $2.74, up 7.45 percent from its previous close of $2.55. The stock is up after the news of the company?s decision to sell its East Texas assets. Gastor Exploration shows bullish trend as it made the upward move with trading volume of 351,132 shares, in contrast to the average daily trading volume of 712,310 shares. Its bullish trend is further confirmed by its MACD chart and the stock is also trading above its 20 days SMA of $2.72.

Gastor Exploration stock is highly volatile with its beta at 1.57. The company?s market capitalization is at $186.18 million.

Get more news and reports on how to successfully trade GST here:

http://www.monstertradingalerts.com/market-scan/?symbol=GST

ABOUT US:

MonsterTradingAlerts.com issues momentum alerts on stocks that can provide gains to day traders. MonsterTradingAlerts.com provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more. MonsterTradingAlerts.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals MonsterTradingAlerts.com is often in the know of several large investor awareness campaigns being deployed.

Timing is everything when trading Penny Stocks. Gain an Edge by joining the MonsterTradingAlerts.com newsletter and receiving alerts from a Pro-Active team of researchers. Trading Alerts believes traders should have a chance at successfully trading penny stocks and invites traders and investors to be part of the Free VIP membership.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.MonsterTradingAlerts.com

Disclosure: MonsterTradingAlerts.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit MonsterTradingAlerts.com website, for complete risks and disclosures.

Investor Alley, its employees, officers, directors, shareholders and affiliates, hold no positions in the above-mentioned stocks.

For full disclaimer visit; http://www.monstertradingalerts.com/disclaimer/

Contact Info:
Alexander K. Neumann
Monster Trading Alerts
[email protected]
347-905-5009


© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BIOCRYST PHARMACEUTICALS,
04/05BIOCRYST PHARMACEUTICALS : Peramivir, Rapivab
AQ
04/02BIOCRYST PHARMACEUTICALS : Files Definitive Proxy Statement in Connection with P..
BU
03/20BIOCRYST PHARMACEUTICALS : Announces Initiation of the Phase 3 APeX-2 Trial of B..
AQ
03/16BIOCRYST PHARMACEUTICALS : Announces Initiation of the Phase 3 APeX-2 Trial of B..
AQ
03/15BIOCRYST PHARMACEUTICALS, INC. (NASD : BCRX) Files An 8-K Other Events
AQ
03/15BIOCRYST PHARMACEUTICALS INC : Other Events, Financial Statements and Exhibits (..
AQ
03/15BioCryst Announces Initiation of the Phase 3 APeX-2 Trial of BCX7353 in Patie..
GL
03/12BIOCRYST PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CON..
AQ
03/05BIOCRYST PHARMACEUTICALS : Announces Initiation of the APeX-S Long-Term Safety T..
AQ
03/01BIOCRYST PHARMACEUTICALS : Announces Initiation of the APeX-S Long-Term Safety T..
AQ
More news
News from SeekingAlpha
04/10BioCryst and Idera postpone shareholder meetings for merger vote until July 1.. 
03/16YOUR DAILY PHARMA SCOOP : Abeona Update, Alexion Data, Solid Biosciences Setback 
03/15BioCryst launches late-stage study of BCX7353 in HAE 
03/02YOUR DAILY PHARMA SCOOP : Portola Drops On AndexXa Update, NovaVax Top-Line Resu.. 
02/28BioCryst commences long-term safety study of BCX7353 in HAE patients; shares .. 
Financials ($)
Sales 2018 17,8 M
EBIT 2018 -77,5 M
Net income 2018 -83,4 M
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales 2018 28,5x
Capi. / Sales 2019 27,7x
Capitalization 507 M
Chart BIOCRYST PHARMACEUTICALS,
Duration : Period :
BioCryst Pharmaceuticals,  Technical Analysis Chart | BCRX | US09058V1035 | 4-Traders
Technical analysis trends BIOCRYST PHARMACEUTICALS,
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 7,83 $
Spread / Average Target 52%
EPS Revisions
Managers
NameTitle
Jon P. Stonehouse President, Chief Executive Officer & Director
Robert Alexander Ingram Chairman
Robert Bennett Vice President-Investor Relations & Operations
Thomas R. Staab CFO, Treasurer, Principal Accounting Officer & SVP
William P. Sheridan Chief Medical Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
BIOCRYST PHARMACEUTICALS, INC.5.50%507
GILEAD SCIENCES5.35%98 675
VERTEX PHARMACEUTICALS10.10%41 476
REGENERON PHARMACEUTICALS-14.19%34 613
GENMAB15.65%12 876
BEIGENE LTD (ADR)73.08%9 059